A selective inhibitor of cyclin-dependent kinases 4/6,ribociclib,for the treatment of breast cancer
LI Yan
CUI Ying-jie
LIU Juan-juan
ZHAO Hui
WANG Zhen-zhen
ZHOU Yi
ZHANG Jing
Abstract：Ribociclib is a selective,orally bioavailable small molecule inhibitor of cyclin-dependent kinases 4/6(CDK4/6),which was approved by the National Medical Products Administration on January 19,2023,and officially launched in China on February 18,2023.It is indicated for the treatment of locally advanced or metastatic breast cancer that is hormone receptor-positive and human epidermal growth factor receptor 2-negative(HR+/HER2-).Ribociclib is the first and currently the only CDK4/6 inhibitor approved for initial treatment of premenopausal and perimenopausal patients with breast cancer in China.This article reviews the mechanism of action,pharmacokinetics,pharmacodynamics,clinical studies,and safety evaluation of this drug,with the aim of providing references for new drug development and clinical application of ribociclib.
Keywords：ribociclibcyclin-dependent kinases 4/6 small molecule inhibitorbreast cancer
Publication Date：2025-02-27
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：6( 364-369 )